Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T13:35:42.158Z.
Calculation as of: 2026-10-06T13:35:42.158Z.
Quote observation: 2026-10-06T13:34:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$287.18M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$278.01M
Operating Cash Flow Yield
N/A
TTM Avg
41.23%
3Y Avg
41.23%
5Y Avg
41.23%
Market Cap
$283.82M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.87M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$291.25M
Operating Cash Flow Yield
N/A
TTM Avg
1.81%
3Y Avg
1.81%
5Y Avg
1.81%
Market Cap
$283.06M
Operating Cash Flow Yield
N/A
TTM Avg
1.84%
3Y Avg
1.84%
5Y Avg
1.84%
Market Cap
$279.05M
Operating Cash Flow Yield
N/A
TTM Avg
2.67%
3Y Avg
2.67%
5Y Avg
2.67%
Market Cap
$272.75M
Operating Cash Flow Yield
N/A
TTM Avg
21.89%
3Y Avg
21.13%
5Y Avg
21.13%
Market Cap
$306.12M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $287.18M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $278.01M | N/A | 41.23% | 41.23% | 41.23% |
| Fate Therapeutics, Inc. (FATE)vs › | $283.82M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $291.25M | N/A | 1.81% | 1.81% | 1.81% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.06M | N/A | 1.84% | 1.84% | 1.84% |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | N/A | 2.67% | 2.67% | 2.67% |
| AC Immune S.A. (ACIU)vs › | $272.75M | N/A | 21.89% | 21.13% | 21.13% |
| Standard BioTools Inc. (LAB)vs › | $306.12M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $267.99M | N/A | 3.96% | 3.96% | 3.96% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
